Keyword: drug development

This page displays contents related to the keyword.

InFLAMES - Solution is in Immunity

InFLAMES - Solution is in Immunity

The InFLAMES Flagship (Innovation Ecosystem based on the Immune System) is a joint effort of University of Turku and Åbo Akademi University aiming at being an internationally recognized, top-level, immunological research and development cluster which will be globally attractive both for the researchers and business partners.

To the InFLAMES home page >>

 

Juha Laine and Timo Veromaa Appointed as Professors of Practice at the University of Turku

19.04.2021

Docent Juha Laine has been appointed as Professor of Practice in Pharmacoeconomics and Dr. Timo Veromaa Professor of Practice in Drug Development. The appointments strengthen the operations of the InFLAMES Flagship, joint effort of the University of Turku and Åbo Akademi University, funded by the Academy of Finland. Both professors of practice have been offered part-time positions for the duration of the InFLAMES Flagship funding period.

Promising Results from First-in-Humans Study of a Novel PET Radiopharmaceutical - Study Continues with Rheumatoid Arthritis Patients

16.04.2021

The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe.

A Novel Folic Acid Linked Drug Has Shown to Attenuate Inflammation and Disease Activity in Animal Model of Multiple Sclerosis

01.02.2021

Recently published research has indicated that folate receptor targeting therapy constrains inflammation in inflammatory demyelinating central nervous system lesions and may inhibit progression of the disease in animal model of multiple sclerosis (MS). This research has been conducted in co-operation with Turku PET Centre, Purdue University and Endocyte Inc (now part of Novartis Institutes for BioMedical Research, NIBR).

Doctoral Candidates of Drug Research Trained in Close Collaboration with the Industry

08.10.2020

In 2019, the University of Turku launched a new doctoral training in collaboration with partners from the drug industry. A major part of the training is carried out in an industrial environment. The training also includes postgraduate studies and academic secondments in the University’s research groups. The training educates experts specialised in industrial research and product development.